Jim Cramer: Buy Amazon, CBS, and These 2 Biotech Stocks

Jim Cramer made the following calls on September 26th, 2013. What do you think about his picks?

Amazon.com Inc. (NASDAQ:AMZN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 4, 2013. The stock’s 52-week high is $320.57, and its 52-week low is $218.18. According to Cramer, Amazon’s stock has a value that defies logic, but he still claimed that the company was a buy. The stock’s price has rebounded nicely during this month after losing points in August, and many are looking forward to the holiday season to fuel Amazon’s sales.

amzn-20130927

CBS Corporation (NYSE:CBS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on October 5, 2012. The stock’s 52-week high is $57.47, and its 52-week low is $31.84. Cramer expressed optimism about CBS, saying that the company has done a good job managing their affairs and that they have been very “forward looking.” The company recently came out ahead in negotiations over transmission fees with Time Warner Cable (NYSE:TWC), and they have also signed up to partner with Twitter’s Amplify as part of their promotions for their new fall lineup.

cbs-20130927

Biogen Idec Inc. (NASDAQ:BIIB): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 5, 2013. The stock’s 52-week high is $248.95, and its 52-week low is $134.00. It’s been a great year for Biogen, a stock that Cramer says can only go higher as fund managers look to show that it is part of their portfolios. He reiterated his stamp of approval on the stock, which has surged by over 10 percent this month alone.

biib-20130927

Celgene Corporation (NASDAQ:CELG): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 4, 2013. The stock’s 52-week high is $151.95, and its 52-week low is $71.23. Cramer was a fan of the hottest biotech stocks of this year, Celgene. A subsidiary of the company is due to present its latest findings concerning apremilast, which can treat certain types of arthritis, at a conference near the end of October.

celg-20130927

Don’t Miss: How Facebook’s ‘New First Screen’ Approach Is Winning

More from The Cheat Sheet